Metrics to compare | 301065 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship301065PeersSector | |
|---|---|---|---|---|
P/E Ratio | 25.5x | 21.0x | −0.3x | |
PEG Ratio | 1.51 | 0.14 | 0.00 | |
Price/Book | 1.4x | 2.4x | 2.6x | |
Price / LTM Sales | 3.0x | 2.9x | 3.0x | |
Upside (Analyst Target) | - | 34.6% | 58.2% | |
Fair Value Upside | Unlock | 17.5% | 7.5% | Unlock |
Zhejiang Benli Technology Co., Ltd. engages in the research, development, production, and sales of pharmaceutical, pesticide, and new material intermediates in China and internationally. Its products include 2,4-Dichloro-5-fluorobenzoyl chloride, 2-(2,4-Dichloro-5-fluorobenzoyl)-3-cyclopropylamine ethyl acrylate, 1-Ethyl-7-(1-piperazinyl) -6-fluoro-1, 4-dihydro-4-oxo-3-quinolinecarboxylic acid hydrochloride, 2,4-Dichlorofluorobenzene, and Methyl 3-methoxyacrylate; and Ethyl N,N-dimethylaminoacrylate, 2,6-Dichlorofluorobenzene, and 3-(2-Ethylene Glycol Methyl Ether)-2-Methyl -4-Methanesulfonyl benzoic acid. The company was founded in 2011 and is based in Linhai, China.